Literature DB >> 11821635

Factors influencing the systolic blood pressure response to drug therapy.

Carlos Campo1, Julián Segura, Luis M Ruilope.   

Abstract

In the early stage of hypertension, diastolic blood pressure has greater prognostic importance, but in the elderly, systolic blood pressure is the most important marker of cardiovascular complications. Therefore, the need for more strict control of this component of blood pressure must be reconsidered. The benefit obtained in different studies in the elderly suggests that the treatment of isolated systolic hypertension is associated with a reduction in overall cardiovascular mortality of 22%, in coronary heart disease mortality of 26%, and in stroke mortality of 33%. However, a higher percentage of patients (73%) attain the diastolic goal of <90 mm Hg, while only 34% have systolic pressure reduced to <140 mm Hg. In a review of randomized trials comparing at least four different antihypertensive drugs, significant differences in systolic blood pressure reduction have not been demonstrated, except in black populations, in whom calcium channel blockers and diuretics seem to be more effective. In patients with isolated systolic hypertension, data are inconclusive, but calcium channel blockers and diuretics appear to lower blood pressure to a greater degree than do other antihypertensive drugs. Two main predictors of difficulty in controlling systolic blood pressure are the baseline blood pressure and the presence of diabetes. Other predictors are the duration of arterial hypertension, older age, the presence of target organ damage and associated clinical conditions (myocardial infarction, stroke, chronic renal failure), and an elevated serum uric acid level. It appears that the profile of patients with a poorer therapeutic response includes a greater severity of hypertension and/or the presence of cardiovascular disease. (c) 2002 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821635      PMCID: PMC8101875          DOI: 10.1111/j.1524-6175.2002.00487.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  53 in total

1.  A comparison of four primary classes of antihypertensive monotherapy in Thai patients.

Authors:  A Sukonthasarn
Journal:  J Med Assoc Thai       Date:  2000-10

2.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

Authors:  B Dahlöf; L H Lindholm; L Hansson; B Scherstén; T Ekbom; P O Wester
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

3.  Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians.

Authors:  C J O'Donnell; P M Ridker; R J Glynn; K Berger; U Ajani; J E Manson; C H Hennekens
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

4.  Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.

Authors:  L Hansson; T Hedner; P Lund-Johansen; S E Kjeldsen; L H Lindholm; J O Syvertsen; J Lanke; U de Faire; B Dahlöf; B E Karlberg
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

5.  Influence of diabetes and type of hypertension on response to antihypertensive treatment.

Authors:  M J Brown; A Castaigne; P W de Leeuw; G Mancia; C R Palmer; T Rosenthal; L M Ruilope
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

Review 6.  Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations.

Authors:  H R Brunner; J Ménard; B Waeber; M Burnier; J Biollaz; J Nussberger; M Bellet
Journal:  J Hypertens       Date:  1990-01       Impact factor: 4.844

7.  Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; D Levy
Journal:  Hypertension       Date:  1999-09       Impact factor: 10.190

8.  STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension.

Authors:  B Dahlöf; L Hansson; L H Lindholm; B Scherstén; P O Wester; T Ekbom; T Hedner; U de Faire
Journal:  Blood Press       Date:  1993-06       Impact factor: 2.835

9.  Influence of hypotensive drug treatment in elderly hypertensives: study terminating events in the trial of the European Working Party on High Blood Pressure in the Elderly.

Authors:  A Amery; W Birkenhäger; P Brixko; C Bulpitt; D Clement; P de Leeuw; J F De Plaen; M Deruyttere; A De Schaepdryver; C Dollery
Journal:  J Hypertens Suppl       Date:  1985-12

10.  Factors predictive of attendance at clinic and blood pressure control in hypertensive patients.

Authors:  P Degoulet; J Menard; H A Vu; J L Golmard; C Devries; G Chatellier; P F Plouin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-09
View more
  3 in total

1.  Blood pressure control and cardiovascular risk in hypertensive patients with type 2 diabetes: The German T2Target registry.

Authors:  Thomas Mengden; Uwe Ligges; Johanna Mielke; Peter Bramlage; Andrea Korzinek; Walter Sehnert
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-11       Impact factor: 3.738

2.  Magnitude and determinants of uncontrolled blood pressure among hypertensive patients in Ethiopia: hospital-based observational study.

Authors:  Tadesse M Abegaz; Ousman A Abdela; Akshaya S Bhagavathula; Fitsum S Teni
Journal:  Pharm Pract (Granada)       Date:  2018-06-22

Review 3.  Who should be treated with combination therapy as initial treatment for hypertension?

Authors:  George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.